SCHEMBL6328744

SCHEMBL6328744

CC(S)CNS(=O)(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.55
CA2 P00918 5/20 0.55
ALDH1A1 P00352 9/20 0.54
GRIA4 P48058 2/20 0.53
HTT P42858 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
ALOX15 P16050 1/20 0.50
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
UQCRB P14927 1/20 0.49
TP53 P04637 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
GBA1 P04062 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324136 0.86 CA1 (0.75) CA1CA2ALDH1A1SMN1; SMN2LMNA
SCHEMBL6323468 0.81 GBA1 (0.70) CA1CA2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6324078 0.80 SIGMAR1 (0.51) CA1CA2ALDH1A1GBA1TSHR
SCHEMBL6326226 0.80 CA1 (0.53) CA1CA2ALDH1A1SMN1; SMN2LMNA
SCHEMBL6329766 0.80 CA1 (0.73) CA1CA2ALDH1A1SMN1; SMN2LMNA
SCHEMBL6323694 0.80 CA1 (0.71) CA1CA2ALDH1A1HTTSMN1; SMN2
SCHEMBL6320964 0.80 CA1 (0.71) CA1CA2ALDH1A1GBA1TSHR
SCHEMBL6323680 0.80 GBA1 (0.57) CA1CA2ALDH1A1GRIA4SMN1; SMN2
SCHEMBL6329695 0.79 ALDH1A1 (0.57) CA1CA2ALDH1A1KMT2AGBA1
SCHEMBL6498413 0.78 ALDH1A1 (0.63) CA1CA2ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA1 196/4885CA2 492/4885ALDH1A1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.